Gaingels

Gaingels is a venture investment syndicate founded in 2014 and based in Burlington, Vermont, dedicated to supporting the LGBT+ community and its allies. The organization invests in companies led by LGBT+ founders and executives at all stages of development, as well as in established firms committed to enhancing their diversity and inclusivity. With a global portfolio comprising over 130 companies and $70 million in investment capital deployed, Gaingels plays a vital role in fostering an inclusive business environment. Additionally, the Gaingels network actively assists its portfolio companies in identifying and recruiting diverse talent for their leadership teams, while cultivating a vibrant community of industry leaders, investors, and entrepreneurs committed to driving positive social change through business initiatives.

Marc Baum

Investor

Jesse Curran

Principal

Ashley Flucas

Venture Partner

Rachael Foo

Investor

Todd Havill

Research Operations and Principal, Investment

Surya Jayaweera

Angel Investor

Jennifer Jeronimo

CEO and General Partner

Chris Leiter

Venture Partner and Investor

Jake Prigoff

General Partner

Alexandra Tanner

Investor

Past deals in Maryland

VerImmune

Seed Round in 2024
VerImmune, based in Baltimore, Maryland, is an immuno-oncology company focused on developing innovative cancer therapies through its proprietary technology, Anti-tumor Immune Redirection Virus-inspired Particles (AIR-ViPs). This unique approach aims to harness pre-existing immune memory from pathogens or childhood vaccines to target and redirect the immune system toward tumors. By doing so, VerImmune seeks to address significant challenges in cancer treatment, particularly for patients with limited options or those who have developed resistance to conventional therapies. The company's strategy promises to offer low toxicity and sustained benefits across a diverse range of cancer types, potentially transforming the treatment landscape for those with difficult-to-treat malignancies.

VerImmune

Seed Round in 2023
VerImmune, based in Baltimore, Maryland, is an immuno-oncology company focused on developing innovative cancer therapies through its proprietary technology, Anti-tumor Immune Redirection Virus-inspired Particles (AIR-ViPs). This unique approach aims to harness pre-existing immune memory from pathogens or childhood vaccines to target and redirect the immune system toward tumors. By doing so, VerImmune seeks to address significant challenges in cancer treatment, particularly for patients with limited options or those who have developed resistance to conventional therapies. The company's strategy promises to offer low toxicity and sustained benefits across a diverse range of cancer types, potentially transforming the treatment landscape for those with difficult-to-treat malignancies.

Previse

Seed Round in 2023
Capsulomics, LLC is a biotechnology company focused on developing and manufacturing DNA tests for the early detection of upper gastrointestinal (GI) cancers, particularly esophageal cancer and its precancerous condition, Barrett’s esophagus. Founded in 2018 and based in Halethorpe, Maryland, Capsulomics aims to address the diagnostic and prognostic uncertainties associated with GI diseases. By providing advanced diagnostic solutions, the company enables healthcare professionals to prevent, detect, and treat these conditions more effectively, ultimately enhancing patient outcomes.

VerImmune

Seed Round in 2022
VerImmune, based in Baltimore, Maryland, is an immuno-oncology company focused on developing innovative cancer therapies through its proprietary technology, Anti-tumor Immune Redirection Virus-inspired Particles (AIR-ViPs). This unique approach aims to harness pre-existing immune memory from pathogens or childhood vaccines to target and redirect the immune system toward tumors. By doing so, VerImmune seeks to address significant challenges in cancer treatment, particularly for patients with limited options or those who have developed resistance to conventional therapies. The company's strategy promises to offer low toxicity and sustained benefits across a diverse range of cancer types, potentially transforming the treatment landscape for those with difficult-to-treat malignancies.

Sonavi Labs

Seed Round in 2021
Sonavi Labs, Inc. is a Baltimore-based company that specializes in the development of medical devices and artificial intelligence-based software aimed at respiratory monitoring and diagnostic support. Founded in 2017, the company focuses on creating innovative products that analyze body sounds to assist in the diagnosis of respiratory diseases. By leveraging advanced technology, Sonavi Labs enables healthcare providers to detect, monitor, and potentially predict respiratory conditions by identifying abnormalities in the sounds produced by the body. This approach enhances the capabilities of medical professionals and aims to improve the patient experience in managing respiratory health.

Protenus

Series D in 2021
Protenus, Inc. is a company based in Baltimore, Maryland, that specializes in developing a compliance analytics platform for healthcare organizations in the United States. Founded in 2014, Protenus utilizes artificial intelligence to audit access to patient records, helping to identify risks such as inappropriate access and the misuse of controlled substances by hospital staff. The platform enables healthcare providers to proactively detect policy violations and anomalous behaviors, ultimately supporting safer patient outcomes while safeguarding the integrity of health data. Through its innovative solutions, Protenus aims to reduce risk and protect the reputation of healthcare organizations, affirming its commitment to both patient safety and organizational accountability.

Qualytics

Seed Round in 2021
Qualytics is a company that specializes in data quality surveillance technology aimed at monitoring and preventing data pipeline corruption. Founded in 2020 in Baltimore, Maryland, it offers a robust data firewall that captures erroneous data at the source, ensuring that flawed information does not infiltrate downstream data platforms. The technology integrates data pipelines, data flows, and a surveillance hub, utilizing machine learning to automatically generate and adapt data rules through supervised workflows. This allows organizations to detect and respond to anomalies in real-time, employing active measures such as message-level quarantining to safeguard data integrity.

Previse

Funding Round in 2020
Capsulomics, LLC is a biotechnology company focused on developing and manufacturing DNA tests for the early detection of upper gastrointestinal (GI) cancers, particularly esophageal cancer and its precancerous condition, Barrett’s esophagus. Founded in 2018 and based in Halethorpe, Maryland, Capsulomics aims to address the diagnostic and prognostic uncertainties associated with GI diseases. By providing advanced diagnostic solutions, the company enables healthcare professionals to prevent, detect, and treat these conditions more effectively, ultimately enhancing patient outcomes.

Sonavi Labs

Venture Round in 2020
Sonavi Labs, Inc. is a Baltimore-based company that specializes in the development of medical devices and artificial intelligence-based software aimed at respiratory monitoring and diagnostic support. Founded in 2017, the company focuses on creating innovative products that analyze body sounds to assist in the diagnosis of respiratory diseases. By leveraging advanced technology, Sonavi Labs enables healthcare providers to detect, monitor, and potentially predict respiratory conditions by identifying abnormalities in the sounds produced by the body. This approach enhances the capabilities of medical professionals and aims to improve the patient experience in managing respiratory health.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.